🇺🇸 FDA
Pipeline program

Buprenorphine Transdermal System

BP08-CN-001

Phase 3 small_molecule completed

Quick answer

Buprenorphine Transdermal System for Disease (or Disorder); Intervertebral Disc, With Myelopathy (Manifestation) is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Disease (or Disorder); Intervertebral Disc, With Myelopathy (Manifestation)
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials